相关实验视频
Updated: Dec 10, 2025
08:18
Preparation of Naringenin Solution for In Vivo Application
Published on: August 10, 2021
3.7K
可溶性忍素-1 改善动脉样的抗炎作用
Sejin Jeon1, Tae Kyeong Kim1, Se-Jin Jeong2
1Immune and Vascular Cell Network Research Center, National Creative Initiatives, Department of Life Sciences (S.J., T.K.K., M.-N.L., S.-K.S., S.S., J.J., H.Y.K., S.K., G.T.O.), Ewha Womans University, Seoul, Korea.
Circulation
|September 5, 2020
概括
神经损伤诱导蛋白1 (Ninjurin-1或Ninj1) 是巨细胞中的新型矩阵金属蛋白酶9基质. 可溶性Ninj1 (sNinj1) 作为动脉动脉保护蛋白,减少动脉样硬化中的炎症和单细胞招募.
科学领域:
- 心血管生物学
- 免疫学
- 分子医学
背景情况:
- 巨细胞通过产生与炎症相关的分子在动脉样硬化中发挥关键作用.
- 这些分子由矩阵金属蛋白酶 (MMP) 释放,从而导致疾病的进展.
- 忍-1 (Ninj1) 是一种新的MMP-9基质,研究其在动脉样硬化中的作用.
研究的目的:
- 研究Ninj-1表达和动脉样硬化进展之间的关系.
- 确定Ninj1在巨介导炎症和单细胞招募中的功能作用.
- 探索可溶性Ninj1 (sNinj1) 和其模仿剂在动脉样硬化中的治疗潜力.
主要方法:
- 在人类和小鼠动脉样硬化组织和血清中评估Ninj1表达.
- 使用了Ninj1缺乏的Apoe-/-小鼠和骨髓移植模型 (Ldlr-/-小鼠).
- 对巨和小鼠进行sNinj1模拟 (ML56,PN12).
主要成果:
- 人类和小鼠的Ninj1表达与动脉样硬化病变的程度相关.
- 在巨细胞中Ninj1缺乏促进了促炎信号和增加单细胞的招募.
- 通过MMP-9裂变产生的sNinj1在体外和体内表现出抗动脉硬化作用.
- 在小鼠中,sNinj1- 模仿性降低了炎症和单细胞迁移,并缓解了动脉样硬化.
结论:
- Ninj1 是巨细胞中的一种新型MMP-9基质,而sNinj1 是一种动脉保护性分泌蛋白质.
- sNinj1 调节巨细胞炎症和单细胞招募,影响动脉样硬化.
- sNinj1的抗炎作用保留在人类巨细胞中,与人类动脉样硬化有关.
相关概念视频
01:26Atherosclerosis III: Management
226
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
226
01:38Inflammation
60.6K
Overview
60.6K
01:23Atherosclerosis IV: Nursing Management
226
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
226
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
737
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
737
01:23Antihypertensive Drugs: Vasodilators
1.8K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.8K
01:30Atherosclerosis I: Introduction
560
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
560